Adult; Blood Glucose/drug effects/metabolism; Body Mass Index; Diabetes Mellitus/blood/drug therapy; Diabetes Mellitus, Type 2/blood; Double-Blind Method; Female; Fenfluramine/pharmacology; Glucose Clamp Technique; Humans; Insulin/blood; Male; Middle Aged; Obesity
Abstract :
[en] OBJECTIVE: To study the short-term effects of the serotoninergic anorectic drug d-fenfluramine on insulin-induced glucose disposal. RESEARCH DESIGN AND METHODS: A randomized double-blind placebo-controlled crossover trial with 1-wk treatment periods (2 x 15 mg/day d-fenfluramine) was conducted. Twenty obese subjects, 10 with normal oral glucose tolerance and 10 with non-insulin-dependent diabetes mellitus (NIDDM), were all treated with a weight-maintaining diet. Euglycemic-hyperinsulinemic glucose clamps with measurement of glucose kinetics with D-[3-3H]glucose were performed at either two (patients without NIDDM, 0.05 and 0.10 U.kg-1.h-1) or three (patients with NIDDM, 0.05, 0.10, and 0.50 U.kg-1.h-1) insulin delivery rates. RESULTS: In the nondiabetic subjects, no significant changes in any metabolic or hormonal parameter were measured in the basal state or during the clamp despite a slight reduction in body weight (-1.2 +/- 0.5 kg, P less than 0.05). In the diabetic patients, no significant changes in body weight or basal plasma insulin levels were observed, but fasting blood glucose levels (8.0 +/- 0.8 vs. 9.4 +/- 1.1 mM, P less than 0.005) and plasma free fatty acid concentrations (1150 +/- 227 vs. 1640 +/- 184 microM, P less than 0.05) were significantly reduced after d-fenfluramine compared with placebo. During the clamp, insulin metabolic clearance rate (MCR) was similar after both placebo and d-fenfluramine; endogenous (hepatic) glucose production was similarly and almost completely suppressed, whereas glucose disposal was remarkably enhanced after d-fenfluramine (average increase of glucose MCR 35 +/- 12%, P less than 0.02). CONCLUSIONS: Whatever the mechanism(s) involved, a 1-wk treatment with d-fenfluramine induces better blood glucose control and improves insulin sensitivity in obese patients with NIDDM independent of significant weight reduction; this last effect is not present in obese subjects with normal oral glucose tolerance.
Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale
Paolisso, G.
Salvatore, T.
Lefebvre, Pierre ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques
Language :
English
Title :
Improvement of insulin-induced glucose disposal in obese patients with NIDDM after 1-wk treatment with d-fenfluramine.
Publication date :
1991
Journal title :
Diabetes Care
ISSN :
0149-5992
eISSN :
1935-5548
Publisher :
American Diabetes Association, Alexandria, United States - Virginia
Rowland NE, Carlton J: Neurobiology of an anorectic drug: fenfluramine. Prog Neurobiol (NY) 27:13-62, 1986
Jorgensen KD: Actions of fenfluramine on glucose uptake in vitro and in vivo. Acta Pharmacol Toxicol 40:401-17, 1977
Turtle JR, Burgess JA: Hypoglycemic action of fenfluramine in diabetes mellitus. Diabetes 22:858-67, 1973
Wales JK: The effect of fenfluramine on obese, maturityonset diabetic patients. Curr Med Res Opin 6 (Suppl. 1):235-66, 1979
Dykes JRW: The effect of a low-calorie diet with and without fenfluramine on the glucose tolerance and insulin secretion of obese maturity onset diabetes. Postgrad Med J 49:318-24, 1973
Verdy M, Charboneau L, Verdy I, Belanger R, Boite E, Chiasson JL: Fenfluramine in the treatment of non-insulin dependent diabetics: hypoglycemic versus anorectic effect. Int J Obes 7:289-97, 1983
Pestell RG, Crock PA, Ward GM, Alford FP, Best JD: Fenfluramine increases insulin action in patients with NIDDM. Diabetes Care 12:252-58, 1989
Storlien LH, Thorburn AW, Smythe GA, Jenkins AB, Chisholm DJ, Kraegen EW: Effect of d-fenfluramine on basal glucose turnover and fat-feeding - induced insulin resistance in rats. Diabetes 38:499-503, 1989
Mennini T, Garattini S, Caccia S: Anorectic effect of fenfluramine isomers and metabolites: relationship between brain levels and in vitro potencies on serotoninergic mechanisms. Psychopharmacology 85:111-14, 1985
National Diabetes Data Group: Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28:1039-57, 1979
DeFronzo RA, Tobin JD, Andres R: Glucose-clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-23, 1979
Verdonk CA, Rizza RA, Westland RL, Nelson RL, Gerich JE, Service FJ: Glucose clamp using the Biostator GCIIS. Horm Metab Res 12:133-35, 1980
Verdin E, Castillo M, Luyckx AS, Lefèbvre PJ: Similar metabolic effects of pulsatile versus continuous human insulin delivery during euglycemic, hyperinsulinemic glucose clamp in normal man. Diabetes 33:1169-74, 1984
Hales CN, Randle PJ: Immunoassay of insulin with insulin antibody precipitate. Biochem J 88:137-46, 1963
Luyckx AS: Immunoassays for glucagon. In Glucagon, Molecular Physiology, Clinical and Therapeutic Implications. Lefèbvre PJ, Unger RH, Eds. Oxford, UK, Pergamon, 1972, p. 258-98
Heding LG: Radioimmunological determination of human C-peptide in serum. Diabetologia 11:541-48, 1975
Sulon J, Demey-Ponsart E, Beauduin P, Sodoyez JC: Radioimmunoassay of corticosterone, cortisol and cortisone: their application to human cord and maternal plasma. J Steroid Biochem 9:671-76, 1978
Reuter A, Vrindts-Gevaert Y, Joris J, Chretien M, Franchimont P: In Radioimmunoassay of B-Endorphins and B-Lipotropins. Amsterdam, Excerpta Med., 1984, p. 1092 (Int. Congr. Ser., no. 652)
Eggstein M, Kulhmann E: Triglycerides and glycerol determination after alkaline hydrolysis. In Methods of Enzymatic Analysis. Vol. 4. Bergmeyer HU, Ed. London Academic, 1974, p. 1825-31
Dole VP, Meinertz H: Microdetermination of long chain fatty acids in plasma and tissues. J Biol Chem 235:2595-99, 1960
Schoos R, Schoos-Barbette S, Lambotte C: Dosage of hemoglobin A1c by isoelectrofocusing. Clin Chim Acta 86:61-65, 1978
Steele R: Influence of glucose loading and of injected insulin on hepatic glucose output. Ann NY Acad Sci 82:420-30, 1959
Cobelli C, Mari A, Ferrannini E: Non-steady state: error analysis of Steele's model and development for glucose kinetics. Am J Physiol 252:E679-89, 1987
Groop LC, Bonadonna RC, DelPrato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo RA: Glucose and free fatty acid metabolism in non-insulin-dependent diabetes mellitus: evidence for multiple sites of insulin resistance. J Clin Invest 84:205-13 1989
Ferrannini E, Wahren J, Faber OK, Felig P, Binder C, DeFronzo RA: Splanchnic and renal metabolism of insulin in human subjects: a dose-response study. Am J Physiol 244:E517-27, 1983
Zerbe GO: Randomization analysis of randomized blocks design extended to growth and response curves. Commun Stat 8:A 191-205, 1979
Unger RH, Grundy S: Hyperglycaemia as an inducer as well as a consequence of impaired islet cell function and insulin resistance: implications for the management of diabetes. Diabetologia 28:119-21, 1985
Butterfield WJH, Whichelow MJ: The effects of fenfluramine (Ponderax) on muscle glucose uptake in man (Letter). Lancet 2:109, 1968
Ravussin E, Bogardus C, Schwartz RS, Robbins DC, Wolfe RR, Horton ES, Danforth E Jr, Sims EAH: Thermic effect of infused glucose and insulin in man: decreased response with increased insulin resistance in obesity and non-insulin dependent diabetes mellitus. J Clin Invest 72:893-902, 1983
Randle PJ, Hales CN, Garland PB, Newsholme EA: The glucose fatty-acid cycle: its role in insulin insensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1:785-89, 1963
Felber J-P, Ferrannini E, Golay A, Meyer HU, Thiebaud D, Curchod B, Maeder E, Jequier E, DeFronzo RA: Role of lipid oxidation in pathogenesis of insulin resistance of obesity and type II diabetes. Diabetes 36:1341-50, 1987
Reaven GM, Chen Y-D: Role of abnormal free fatty acid metabolism in the development of non-insulin-dependent diabetes mellitus. Am J Med 85 (Suppl. 5A):106-12, 1988
Sasson S, Kunievsky B, Nathan C, Cerasi E: Failure of fenfluramine to affect basal and insulin-stimulated hexose transport in rat skeletal muscle. Biochem Pharmacol 38:2655-61, 1989